Radiofrequency ablation for Barrett’s esophagus: long-term outcomes

Barrett’s esophagus develops when chronic gastroesophageal reflux changes the lining of the lower esophagus. Although many patients never develop cancer, intestinal metaplasia can progress to high-grade dysplasia and esophageal adenocarcinoma. Radiofrequency ablation (RFA), also called radiofrequency eradication therapy, has become an established endoscopic treatment for selected patients with dysplastic Barrett’s tissue.

The immediate goal is complete eradication of dysplasia and, ideally, complete eradication of intestinal metaplasia. Long-term follow-up asks a broader set of questions: how often the abnormal lining returns, whether cancer risk remains suppressed, which patients need repeat treatment, and how surveillance should continue after apparent treatment success.

Evidence presented through specialist societies such as the International Society for Diseases of the Esophagus helps clinicians interpret these outcomes alongside endoscopic resection, acid suppression, and ongoing monitoring.

How the treatment works

RFA delivers controlled thermal energy through a balloon or focal endoscopic catheter. The energy removes a thin layer of abnormal mucosa while limiting injury to deeper tissue. Healing may allow the esophageal lining to regenerate without the original metaplastic changes.

Visible or nodular lesions should generally be assessed and removed by endoscopic mucosal resection or endoscopic submucosal dissection before ablation. RFA is primarily used for flat, dysplastic Barrett’s mucosa after invasive cancer has been excluded.

Treatment often requires several sessions spaced over weeks or months. High-dose proton pump inhibitor therapy supports healing and reduces acid exposure, while careful endoscopic assessment determines whether residual dysplasia or intestinal metaplasia remains.

What long-term studies show

Randomized trials established that RFA substantially reduces progression from dysplasia to high-grade disease or cancer compared with endoscopic surveillance alone. In patients with high-grade dysplasia, complete eradication of dysplasia is commonly achieved in roughly 80–90% of cases under trial conditions. Complete eradication of intestinal metaplasia is somewhat less consistent.

Longer observational studies indicate that treatment success can remain durable for many years, but recurrence is possible. Recurrent intestinal metaplasia or dysplasia may appear at the original treatment site or elsewhere in the esophagus. Reported recurrence rates vary according to the definition used, biopsy protocol, patient risk profile, and duration of follow-up.

A key finding is that recurrence does not automatically mean treatment failure. Small areas can often be managed with repeat focal ablation or endoscopic resection. The continuing need for surveillance reflects residual risk rather than evidence that RFA lacks lasting value.

Comparing management approaches

The appropriate strategy depends on the grade of dysplasia, visible abnormalities, patient fitness, and the quality of the endoscopic examination. Surgery is now reserved for selected cases, particularly when invasive cancer cannot be treated endoscopically or when disease is extensive and unsuitable for local therapy.

Recurrence and cancer risk

After complete eradication, recurrence may involve buried or newly visible intestinal metaplasia. Dysplastic recurrence is less common than nondysplastic recurrence, but it deserves prompt evaluation because it can precede neoplasia. Any return of abnormal tissue should be confirmed with high-quality endoscopy and targeted biopsies.

The risk of esophageal adenocarcinoma falls substantially after successful RFA, especially when dysplasia was treated early. It does not reach zero. Persistent reflux, a long Barrett’s segment, a hiatal hernia, smoking, obesity, and incomplete eradication may influence the likelihood of recurrence or progression.

Long-term outcomes also depend on the original pathology. Expert review of biopsy specimens can prevent both overtreatment of benign changes and under-treatment of genuine dysplasia. Consistent pathology, imaging, and endoscopic documentation are central to reliable follow-up.

Safety and quality of life

Most adverse effects are temporary. Chest discomfort, painful swallowing, and difficulty swallowing can occur after an ablation session. Esophageal strictures are the most important delayed complication and may require endoscopic dilation. Serious bleeding or perforation is uncommon when treatment is performed by experienced teams.

Patients often value RFA because it avoids the recovery burden of esophagectomy and preserves the esophagus. However, treatment can involve repeated procedures, medication use, dietary adjustments, and anxiety about surveillance findings. Clear preparation and realistic expectations can improve adherence and reduce avoidable interruptions in care.

Follow-up after apparent eradication

Surveillance continues after complete eradication of intestinal metaplasia. Current practice generally uses shorter intervals for patients whose original disease included high-grade dysplasia and somewhat longer intervals for appropriately treated low-grade dysplasia. Exact timing should follow current professional guidance and individualized risk assessment.

At follow-up, the endoscopist examines the previous Barrett’s segment, the gastroesophageal junction, and any scar or irregular mucosa. Biopsies from suspicious areas and systematic sampling help detect recurrence that is not obvious visually. Ongoing acid suppression, weight management when appropriate, smoking cessation, and reflux control support durable results.

Practical priorities for clinicians and patients

• Confirm dysplasia through expert pathology review before committing to an ablation course.
• Remove and stage visible lesions before treating the remaining flat Barrett’s mucosa.
• Use high-quality endoscopy and systematic biopsies to document complete eradication.
• Continue proton pump inhibitor therapy and address reflux, obesity, smoking, and hiatal hernia where relevant.
• Maintain lifelong or guideline-directed surveillance because recurrence and cancer risk are reduced, not eliminated.

Radiofrequency ablation offers a durable reduction in neoplastic risk for carefully selected patients with dysplastic Barrett’s esophagus, especially when paired with expert resection, acid control, and structured surveillance. Review current evidence from esophageal disease specialists and apply it through a multidisciplinary care pathway that matches treatment intensity to each patient’s pathology and long-term risk.